Skip to main content
Have a personal or library account? Click to login
The Elective Genome: What We Owe the Healthy Patient Who Asks to Be Sequenced Cover

The Elective Genome: What We Owe the Healthy Patient Who Asks to Be Sequenced

Open Access
|Oct 2026
Read online

References

  1. Blout Zawatsky CL, Bick D, Bier L, Funke B, Lebo M, Lewis KL, et al. Elective genomic testing: Practice resource of the National Society of Genetic Counselors. J Genet Couns. 2023;32(2):281–299. doi:10.1002/jgc4.1654
  2. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 1963;32:338–343.
  3. Gregg AR, Aarabi M, Klugman S, Leach NT, Bashford MT, Goldwaser T, et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23(10):1793–1806. doi:10.1038/s41436-021-01203-z
  4. Centers for Disease Control and Prevention, Office of Genomics and Precision Public Health. Tier 1 Genomics Applications and Their Importance to Public Health [Internet]. Atlanta: CDC; [cited 2026 Sep 21]. Available from: https://archive.cdc.gov/www_cdc_gov/genomics/implementation/toolkit/tier1.htm
  5. Buchanan AH, Kirchner HL, Schwartz MLB, Kelly MA, Schmidlen T, Jones LK, et al. Clinical outcomes of a genomic screening program for actionable genetic conditions. Genet Med. 2020;22(11):1874–1882. doi:10.1038/s41436-020-0876-4
  6. Cochran M, East K, Greve V, Kelly M, Kelley W, Moore T, et al. A study of elective genome sequencing and pharmacogenetic testing in an unselected population. Mol Genet Genomic Med. 2021;9(9):e1766. doi:10.1002/mgg3.1766
  7. Palao B, Leon-Otegui M, Bernad R, Moreno-Coca M, Ordoñez E, Góngora E, Castilla I, Sogbe M, Beloqui O, Patiño-García A, Cirigliano V, Izquierdo L. Elective genomic screening: results of the implementation of a whole genome sequencing program at a medical check-up unit in Spain. Front Genet. 2026;16:1722462. doi:10.3389/fgene.2025.1722462
  8. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967–975.
  9. de Jong AE, Hendriks YM, Kleibeuker JH, de Boer SY, Cats A, Griffioen G, et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology. 2006;130(3):665–671. doi:10.1053/j.gastro.2005.11.032
  10. Besseling J, Hovingh GK, Huijgen R, Kastelein JJP, Hutten BA. Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality. J Am Coll Cardiol. 2016;68(3):252–260. doi:10.1016/j. jacc.2016.04.054
  11. Guzauskas GF, Garbett S, Zhou Z, Spencer SJ, Smith HS, Hao J, et al. Population genomic screening for three common hereditary conditions: a cost-effectiveness analysis. Ann Intern Med. 2023;176(5):585–595. doi:10.7326/M22-0846
  12. Blumen H, Fitch K, Polkus V. Comparison of treatment costs for breast cancer, by tumor stage and type of service. Am Health Drug Benefits. 2016;9(1):23–32.
  13. Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4(Suppl 1):S73–S77. doi:10.4103/0976-500X.120957
  14. Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Batelaan B, Blagec K, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401(10374):347–356. doi:10.1016/S0140-6736(22)01841-4
  15. Zhu Y, Swanson KM, Rojas RL, Wang Z, St. Sauver JL, Visscher SL, et al. Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases. Genet Med. 2020;22(3):475–486. doi:10.1038/s41436-019-0667-y
  16. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219–1224. doi:10.1038/s41588-018-0183-z
  17. Genetic Information Nondiscrimination Act of 2008, Pub L No. 110–233, 122 Stat 881 (2008).
  18. Miller DT, Lee K, Abul-Husn NS, Amendola LM, Brothers K, Chung WK, et al. ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2023;25(8):100866. doi:10.1016/j.gim.2023.100866.
Language: English
Page range: 316 - 322
Published online: Oct 31, 2026
Published in print: Oct 1, 2026
Published by: European Biotechnology Thematic Network Association
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2026 Luis Izquierdo, Reynir Arngrimsson, Munis Dundar, published by European Biotechnology Thematic Network Association
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.